Emerald Advisers LLC Raises Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Emerald Advisers LLC boosted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 17.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 569,798 shares of the biopharmaceutical company's stock after acquiring an additional 83,116 shares during the period. Ultragenyx Pharmaceutical accounts for 1.2% of Emerald Advisers LLC's holdings, making the stock its 25th biggest position. Emerald Advisers LLC owned 0.69% of Ultragenyx Pharmaceutical worth $31,652,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 67.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 3,318 shares of the biopharmaceutical company's stock worth $155,000 after buying an additional 1,339 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Ultragenyx Pharmaceutical by 113.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 230,767 shares of the biopharmaceutical company's stock worth $10,775,000 after buying an additional 122,412 shares during the last quarter. Capstone Investment Advisors LLC purchased a new position in shares of Ultragenyx Pharmaceutical in the first quarter worth $227,000. GSA Capital Partners LLP purchased a new position in shares of Ultragenyx Pharmaceutical in the first quarter worth $493,000. Finally, Duality Advisers LP raised its holdings in shares of Ultragenyx Pharmaceutical by 1.5% in the first quarter. Duality Advisers LP now owns 39,977 shares of the biopharmaceutical company's stock worth $1,867,000 after buying an additional 606 shares during the last quarter. Hedge funds and other institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ RARE remained flat at $50.99 during trading on Friday. 680,606 shares of the stock traded hands, compared to its average volume of 589,398. The firm's fifty day simple moving average is $55.70 and its two-hundred day simple moving average is $47.97. Ultragenyx Pharmaceutical Inc. has a 1-year low of $34.06 and a 1-year high of $60.37. The firm has a market capitalization of $4.70 billion, a price-to-earnings ratio of -6.98 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.64) by $0.12. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The business had revenue of $147.03 million for the quarter, compared to analyst estimates of $123.20 million. During the same quarter last year, the business earned ($2.25) earnings per share. The company's revenue for the quarter was up 35.7% compared to the same quarter last year. Sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -6.29 EPS for the current year.

Insider Activity

In other news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $50.17, for a total value of $1,003,400.00. Following the sale, the chief executive officer now owns 2,243,985 shares in the company, valued at $112,580,727.45. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, CFO Howard Horn sold 7,465 shares of the firm's stock in a transaction dated Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the transaction, the chief financial officer now directly owns 92,301 shares of the company's stock, valued at approximately $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Emil D. Kakkis sold 20,000 shares of the firm's stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $50.17, for a total transaction of $1,003,400.00. Following the completion of the transaction, the chief executive officer now directly owns 2,243,985 shares in the company, valued at approximately $112,580,727.45. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,556 shares of company stock worth $2,519,367 over the last 90 days. 5.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on RARE. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a report on Thursday, September 26th. Wells Fargo & Company increased their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $75.00 and gave the stock an "overweight" rating in a research note on Friday, August 2nd. Cantor Fitzgerald reiterated an "overweight" rating and issued a $116.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, October 22nd. Canaccord Genuity Group reiterated a "buy" rating and issued a $111.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, July 23rd. Finally, The Goldman Sachs Group increased their price objective on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a "buy" rating in a research note on Friday, August 2nd. Two analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $85.08.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.